Multicenter phase II trial of etoposide in refractory small cell lung cancer

B. F. Issell; L. H. Einhorn; R. L. Comis; R. D. Lawson; L. H. Baker; H. A. Harvey; V. A. Lanzotti; G. L. Wampler; J. R. Daniels; P. N. Anderson

Multicenter phase II trial of etoposide in refractory small cell lung cancer

B. F. Issell, L. H. Einhorn, R. L. Comis, R. D. Lawson, L. H. Baker, H. A. Harvey, V. A. Lanzotti, G. L. Wampler, J. R. Daniels, P. N. Anderson

Department of Medicine

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

Original language	English (US)
Pages (from-to)	127-128
Number of pages	2
Journal	Cancer Treatment Reports
Volume	69
Issue number	1
State	Published - Jul 31 1985

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7873860d9d834be3bf175ee67b216d26,

title = "Multicenter phase II trial of etoposide in refractory small cell lung cancer",

abstract = "The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.",

author = "Issell, {B. F.} and Einhorn, {L. H.} and Comis, {R. L.} and Lawson, {R. D.} and Baker, {L. H.} and Harvey, {H. A.} and Lanzotti, {V. A.} and Wampler, {G. L.} and Daniels, {J. R.} and Anderson, {P. N.}",

year = "1985",

month = jul,

day = "31",

language = "English (US)",

volume = "69",

pages = "127--128",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Multicenter phase II trial of etoposide in refractory small cell lung cancer

AU - Issell, B. F.

AU - Einhorn, L. H.

AU - Comis, R. L.

AU - Lawson, R. D.

AU - Baker, L. H.

AU - Harvey, H. A.

AU - Lanzotti, V. A.

AU - Wampler, G. L.

AU - Daniels, J. R.

AU - Anderson, P. N.

PY - 1985/7/31

Y1 - 1985/7/31

N2 - The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

AB - The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

UR - http://www.scopus.com/inward/record.url?scp=0022007273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022007273&partnerID=8YFLogxK

M3 - Article

C2 - 2981617

AN - SCOPUS:0022007273

SN - 0361-5960

VL - 69

SP - 127

EP - 128

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 1

ER -

Multicenter phase II trial of etoposide in refractory small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this